Harmony Biosciences Holdings, Inc.
HRMYNasdaq
$33.77
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↓ -4.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.5B
P/E
13.6
P/S
2.2
P/B
2.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$899.1M
Net Income (TTM)
$145.6M
Free Cash Flow (TTM)
—
Gross Margin
76.5%
Operating Margin
21.1%
Net Margin
16.2%
ROE
16.0%
ROIC
32.6%
Debt / Equity
0.2
Net Cash
$482.1M
Return 1Y
-7.3%
Company profile
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for patients with rare neurological disorders in the United States. WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- CEO
- John C.s Jacobs
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- Pennsylvania
- Website
- harmonybiosciences.com
Management & directors
- Budur KumarCHIEF MEDICAL OFFICER
- Zaeske Adam H.CHIEF COMMERCIAL OFFICER
- Kapadia SandipCHIEF FINANCIAL OFFICER
- Dayno Jeffrey M.PRESIDENT, CEO
- Serafin AndrewCHIEF STRATEGY OFFICER
Roles derived from SEC Form 4 filings.
Earnings
HRMY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$215.4M↑ +16.6%
Diluted EPS$0.55↓ -29.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Gross profit | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| Operating income | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| Net income | -$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| Diluted EPS | -$2.48 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |
| Operating cash flow | -$3.0M | $98.6M | $144.5M | $219.4M | $219.8M | $348.2M |
| Free cash flow | -$3.0M | $98.3M | $144.3M | $219.1M | $218.7M | $347.9M |
| Gross margin | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| Operating margin | 10.6% | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% |
| Net margin | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $172.8M | $186.0M | $201.3M | $184.7M | $200.5M | $239.5M | $243.8M | $215.4M |
| Gross profit | $140.7M | $143.3M | $146.9M | $152.7M | $162.3M | $179.8M | $175.2M | $170.9M |
| Operating income | $21.4M | $61.7M | $55.7M | $56.2M | $48.2M | $65.5M | $38.6M | $37.3M |
| Net income | $11.6M | $46.1M | $49.5M | $45.6M | $39.8M | $50.9M | $22.5M | $32.5M |
| Diluted EPS | $0.20 | $0.79 | $0.85 | $0.78 | $0.68 | $0.87 | $0.38 | $0.55 |
| Operating cash flow | $42.6M | $70.5M | $75.6M | $34.0M | $79.3M | $108.7M | $126.2M | $27.8M |
| Free cash flow | $42.0M | $70.5M | $75.0M | $33.9M | $79.3M | $108.7M | $126.0M | — |
| Gross margin | 81.4% | 77.0% | 73.0% | 82.7% | 81.0% | 75.1% | 71.9% | 79.3% |
| Operating margin | 12.4% | 33.2% | 27.7% | 30.4% | 24.0% | 27.3% | 15.8% | 17.3% |
| Net margin | 6.7% | 24.8% | 24.6% | 24.7% | 19.8% | 21.2% | 9.2% | 15.1% |
Company news
Jul 16, 2026
- 4d agoHarmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreementstocktwits.com
- 4d agoHarmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transitionfinance.yahoo.com
Jul 15, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-01 | Budur Kumar· CHIEF MEDICAL OFFICER | Tax withholding | 8,882 | $31.83 | $282,714.06 | filing |
| 2026-05-01 | Budur Kumar· CHIEF MEDICAL OFFICER | Option exercise | 18,750 | $0.00 | $0.00 | filing |
| 2026-04-07 | Zaeske Adam H.· CHIEF COMMERCIAL OFFICER | Tax withholding | 3,173 | $27.62 | $87,638.26 | filing |
| 2026-04-07 | Zaeske Adam H.· CHIEF COMMERCIAL OFFICER | Option exercise | 7,500 | $0.00 | $0.00 | filing |
| 2026-01-26 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Sale | 3,746 | $37.15 | $139,171.39 | filing |
| 2026-01-25 | Dayno Jeffrey M.· PRESIDENT, CEO | Tax withholding | 5,654 | $36.82 | $208,180.28 | filing |
| 2026-01-25 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Tax withholding | 2,553 | $36.82 | $94,001.46 | filing |
| 2026-01-25 | Budur Kumar· CHIEF MEDICAL OFFICER | Tax withholding | 1,372 | $36.82 | $50,517.04 | filing |
| 2026-01-25 | Serafin Andrew· CHIEF STRATEGY OFFICER | Tax withholding | 1,126 | $36.82 | $41,459.32 | filing |
| 2026-01-25 | Budur Kumar· CHIEF MEDICAL OFFICER | Option exercise | 2,662 | $0.00 | $0.00 | filing |
| 2026-01-25 | Serafin Andrew· CHIEF STRATEGY OFFICER | Option exercise | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-25 | Dayno Jeffrey M.· PRESIDENT, CEO | Option exercise | 13,000 | $0.00 | $0.00 | filing |
| 2026-01-25 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Option exercise | 4,725 | $0.00 | $0.00 | filing |
| 2026-01-24 | Dayno Jeffrey M.· PRESIDENT, CEO | Tax withholding | 4,785 | $36.82 | $176,183.70 | filing |
| 2026-01-24 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Tax withholding | 2,239 | $36.82 | $82,439.98 | filing |
| 2026-01-24 | Budur Kumar· CHIEF MEDICAL OFFICER | Tax withholding | 1,153 | $36.82 | $42,453.46 | filing |
| 2026-01-24 | Serafin Andrew· CHIEF STRATEGY OFFICER | Tax withholding | 1,116 | $36.82 | $41,091.12 | filing |
| 2026-01-24 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Option exercise | 3,813 | $0.00 | $0.00 | filing |
| 2026-01-24 | Serafin Andrew· CHIEF STRATEGY OFFICER | Option exercise | 2,500 | $0.00 | $0.00 | filing |
| 2026-01-24 | Budur Kumar· CHIEF MEDICAL OFFICER | Option exercise | 2,188 | $0.00 | $0.00 | filing |
| 2026-01-24 | Dayno Jeffrey M.· PRESIDENT, CEO | Option exercise | 10,500 | $0.00 | $0.00 | filing |
| 2026-01-15 | Kapadia Sandip· CHIEF FINANCIAL OFFICER | Sale | 20,961 | $35.92 | $752,833.18 | filing |
| 2025-12-12 | Dayno Jeffrey M.· PRESIDENT, CEO | Sale | 20,000 | $40.11 | $802,146.00 | filing |
| 2025-12-12 | Dayno Jeffrey M.· PRESIDENT, CEO | Sale | 5,933 | $40.11 | $237,956.61 | filing |
| 2025-12-12 | Dayno Jeffrey M.· PRESIDENT, CEO | Option exercise | 20,000 | $8.22 | $164,400.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.